Quince Therapeutics Inc (QNCX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Quince Therapeutics Inc   (NASDAQ: QNCX)


Quince Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Quince Therapeutics Inc 's ROA in the second quarter of 2026?
Quince Therapeutics Inc achieved a return on average assets (ROA) of 81.55 % in its second quarter of 2026, this is above QNCX's average return on assets of -19.54%.
Quince Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $96 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 11 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 42, from total ROA ranking in the first quarter of 2026 at 3296.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 5.79 % -75.14 % 54.57 % -13.14 % -13.07 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 78 78 -3 -15 -15
Return On Assets (TTM) 81.55 % 83.03 % -2.81 % -14.55 % -14.04 %
QNCX's Total Ranking # 42 # 3296 # 3380 # 3390 # 3411
Total Assets (TTM) in million 124 27 123 110 117
Seq. Total Assets Change 365.74 % -78.44 % 12.37 % -6.24 % 9.45 %
Seq. Net Income Change - 461.67 % 25632.61 % - -

QNCX's 5 Years Annual ROA >> Back to QNCX Management Effectiveness >> Compare QNCX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 3
Sector # 12
Overall # 41

Return On Assets Statistics
High Average Low
90.19 %
-19.54 %
-63.42 %
(Mar 31 2026)   (Mar 31 2022)



  News about Quince Therapeutics Inc Return on Assets ROA

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDe...

Quince Therapeutics Unveils Promising Data on EryDex Treatment for Ataxia-Telangiectasia and Reports Encouraging Financial Outlook In the realm of biotechnology, the quest for effective treatments for rare diseases remains one of the most formidable challenges. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage company at the forefront of this endeavor, has recently made significant strides in its mission to unlock innovative therapeutics that harness the body s own biology. This progress is highlighted by the recent publication of data from its Phase 3 ATTeST clinical trial in The Lancet Neurology , which evaluates EryDex a groundbreaking treatment for Ataxia-Telangiectasia (A-T).The ATTeST trial, formally known as the Ataxia-Telangiectasia Trial with the EryDex SysTem (IEDAT-02-2015/NCT02770807), seeks to address the unmet medical needs of patients suffering from A-T, a rare neurodegenerative disorder characterized by progressive movement disorders, immunodeficiency, and an increased risk of malignancies. With the publication of the trial results, Quince Therapeutics provided critical insight into the safety and efficacy of EryDex, which is a formulation of dexamethasone sodium phosphate tailored for optimal delivery and enhanced clinical outcomes.



Financial Statements
Quince Therapeutics Inc 's Assets $ 124 million QNCX's Balance sheet
Quince Therapeutics Inc 's Income $ 0 million Quarterly QNCX's Income Statement
QNCX's Income by Division See QNCX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -18.25 % -31.87 % 58.97 % -21.1 % -55.09 %
Total Assets in million 94 114 168 106 134
Y / Y Net Income Change - - -30.63 % - -
Net Income in million -3 0 0 0 -90
Annual Return On Assets -3.44 % -0.08 % 0.12 % 0.27 % -67.19 %

QNCX's 5 Years Annual ROA >> Back to QNCX Management Effectiveness >> Compare QNCX ROA to its Competitors



More Return On Assets Ratios
QNCX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
QNCX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for QNCX's Competitors
Subscribers only: Roa for Quince Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for QNCX's Customers

You may also want to know
QNCX's Roi QNCX's Inventory Turnover Ratio QNCX's Growth Rates QNCX's Dividend Comparisons
QNCX's Profitability Ratios QNCX's Asset Turnover Ratio QNCX's Dividend Growth
QNCX's Roe QNCX's Valuation Ratios QNCX's Financial Strength Ratios QNCX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Kyntra Bio Inc   156.80 %
Vor Biopharma Inc   154.23 %
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Arbutus Biopharma Corp  82.34 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %

Date modified: 2026-09-26T07:36:44+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.